Celltrion and Must Bio’s Triple Antibody Deal – $3 Billion Down Payment
Deal Details: Celltrion & Must Bio
| Financial Term | Amount (KRW) |
|---|---|
| Upfront Payment | 3 billion |
| Growth Milestones | Up to 39.5 billion |
| Potential Net Sales (upon KRW 10 trillion achievement) | Up to 670 billion |
| Total Potential Value | 712.5 billion |
Celltrion has secured rights to a PD-1xVEGFxIL-2v triple fusion protein candidate antibody from MustBio. This antibody combines PD-1, VEGF, and an IL-2 variant cytokine mechanism. The goal is to develop a “best-in-class” drug capable of targeting all solid carcinomas.
Key Players:
- Celltrion: Acquiring and developing the antibody.
- Must Bio: Original developer of the PD-1xVEGFxIL-2v triple antibody.
- Maengseop Kim: CEO of Must Bio